Metabolic & Cardiometabolic
statins decreases cardiovascular events in primary prevention
In plain terms: Do statins prevent cardiovascular events in people without established cardiovascular disease?
Part of: 💊 statins
Yes, but with smaller absolute benefit: RCTs and meta-analyses show a real ~25-30% relative reduction in first events, though absolute risk reduction is modest in lower-risk populations.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ridker 2008 (JUPITER) venue: N Engl J Med · N Engl J Med | RCT | supports | high | JUPITER: rosuvastatin in 17,802 with normal LDL but elevated hs-CRP cut major CV events 44% (HR 0.56); stopped early, robust but enriched-risk population. |
| Uthman 2025 · Health Technol Assess | meta-analysis | supports | high | Evidence-synthesis of primary-prevention interventions finds statins effective and cost-effective for reducing first cardiovascular events. |
| Taylor Cochrane 2013 · Cochrane Database Syst Rev | meta-analysis | supports | moderate | Cochrane: in primary prevention statins reduced all-cause mortality (OR 0.86) and CV events; authors flagged smaller absolute benefit and possible reporting biases in lower-risk groups. |
| CTT Collaboration 2012 · Lancet | meta-analysis | supports | high | CTT low-risk meta-analysis (27 trials): statins reduced major vascular events ~21% per mmol/L even at 5-year risk below 10%, with benefit exceeding hazards. |
| Sever ASCOT-LLA 2003 · Lancet | RCT | supports | high | ASCOT-LLA: atorvastatin in 10,305 hypertensives with average cholesterol cut nonfatal MI/fatal CHD 36%; stopped early for benefit. |
| Long 2026 · Cardiovasc Drugs Ther | meta-analysis | supports | high | Meta-analysis and meta-regression confirms statins reduce cardiovascular events in primary prevention across trial subgroups. |
| Kalra 2026 · J Clin Lipidol | meta-analysis | supports | high | Meta-analysis of primary-prevention trials shows LDL-C lowering yields larger relative MACE reduction per mmol/L than in secondary prevention. |
| Tanaka 2026 · Eur J Prev Cardiol | meta-analysis | supports | moderate | Review including meta-analytic data finds ~26% reduction in major vascular events per 1 mmol/L LDL-C lowering in older primary-prevention adults. |
| Shepherd WOSCOPS 1995 · N Engl J Med | RCT | supports | high | WOSCOPS: pravastatin in 6,595 hypercholesterolemic men without prior MI cut nonfatal MI/coronary death 31% over ~5 years — first major primary-prevention statin trial. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.